Seminars in arthritis and rheumatism最新文献

英文中文

Exploring the association between adiposity, pain intensity, and effusion-synovitis in people with knee osteoarthritis: A cross-sectional study 探讨膝关节骨关节炎患者肥胖、疼痛强度和积液性滑膜炎之间的关系：一项横断面研究

IF 4.4 2区医学 Q1 RHEUMATOLOGY

Seminars in arthritis and rheumatism

Pub Date : 2026-01-04 DOI: 10.1016/j.semarthrit.2026.152913

YV Raghava Neelapala , C Thomas Appleton , Luciana Macedo , Steve Hanna , Dylan Kobsar , Trevor B Birmingham , Lisa C. Carlesso

Objectives

To examine (i) the association of adiposity with pain intensity and/or effusion-synovitis in people with knee osteoarthritis (OA), adjusting for body mass index (BMI), and (ii) whether indicators of systemic immune inflammation (i.e., the systemic immune-inflammation index (SII) and the systemic immune response index (SIRI)) moderate the above associations.

Methods

Individuals with knee OA were sampled from the Western Ontario Registry for Early Osteoarthritis Knee Study. Total body and visceral fat percentages were measured using bioimpedance analysis, and effusion-synovitis was graded using knee ultrasonography. Multiple regression models with interaction terms were used to examine the association between fat percentages and pain intensity (linear)/effusion-synovitis (logistic), and the interaction effect of fat and SII/SIRI on pain intensity/effusion-synovitis. The analyses were adjusted for confounders (age, sex, BMI, radiographic severity of the opposite knee, and anxio-depressive symptoms).

Results

Data from 225 participants (mean age: 61.1 (10.9), 68% female, mean BMI: 31.7 (7.7)) were analyzed. The associations for adjusted fat and pain intensity models were as follows: total body fat: β): - 0.03 (-0.54 to 0.46) and visceral fat: β (: -0.25 (-1.03 to 0.51)., The odds ratios for adjusted fat and effusion-synovitis models were total body fat: OR): 0.98 (0.92 to 1.05) and visceral fat: OR (): 1.01 (0.91 to 1.11)). Neither the main nor the interaction effects were significant.

Conclusion

Our preliminary results do not support an association of adiposity and its interaction with generalized inflammation with pain/effusion-synovitis adjusted for BMI. Further studies are needed.

目的研究(i)肥胖与膝关节骨性关节炎（OA）患者疼痛强度和/或积液性滑膜炎的相关性，调整体重指数（BMI），以及（ii）系统性免疫炎症指标（即系统性免疫炎症指数（SII）和系统性免疫反应指数（SIRI））是否调节上述相关性。方法从安大略省西部早期骨关节炎膝关节研究登记处抽取患有膝关节炎的个体。使用生物阻抗分析测量全身和内脏脂肪百分比，并使用膝关节超声检查对积液-滑膜炎进行分级。采用带交互项的多元回归模型检验脂肪百分比与疼痛强度（线性）/积液-滑膜炎（logistic）之间的关系，以及脂肪和SII/SIRI对疼痛强度/积液-滑膜炎的交互作用。根据混杂因素（年龄、性别、BMI、对侧膝关节的放射学严重程度和焦虑抑郁症状）对分析进行了调整。结果225名参与者(平均年龄：61.1（10.9)，68%为女性，平均BMI: 31.7(7.7)）的数据被分析。调整后的脂肪和疼痛强度模型的相关性如下：全身脂肪：β): - 0.03(-0.54 ~ 0.46)，内脏脂肪：β(: -0.25（-1.03 ~ 0.51）。调整脂肪和积液-滑膜炎模型的比值比为：全身脂肪：OR: 0.98(0.92 ~ 1.05)，内脏脂肪：OR(): 1.01（0.91 ~ 1.11）。主效应和交互效应均不显著。结论：我们的初步结果不支持肥胖及其与全身炎症（疼痛/积液-滑膜炎）的相互作用的关联。需要进一步的研究。

{"title":"Exploring the association between adiposity, pain intensity, and effusion-synovitis in people with knee osteoarthritis: A cross-sectional study","authors":"YV Raghava Neelapala , C Thomas Appleton , Luciana Macedo , Steve Hanna , Dylan Kobsar , Trevor B Birmingham , Lisa C. Carlesso","doi":"10.1016/j.semarthrit.2026.152913","DOIUrl":"10.1016/j.semarthrit.2026.152913","url":null,"abstract":"<div><h3>Objectives</h3><div>To examine (i) the association of adiposity with pain intensity and/or effusion-synovitis in people with knee osteoarthritis (OA), adjusting for body mass index (BMI), and (ii) whether indicators of systemic immune inflammation (i.e., the systemic immune-inflammation index (SII) and the systemic immune response index (SIRI)) moderate the above associations.</div></div><div><h3>Methods</h3><div>Individuals with knee OA were sampled from the Western Ontario Registry for Early Osteoarthritis Knee Study. Total body and visceral fat percentages were measured using bioimpedance analysis, and effusion-synovitis was graded using knee ultrasonography. Multiple regression models with interaction terms were used to examine the association between fat percentages and pain intensity (linear)/effusion-synovitis (logistic), and the interaction effect of fat and SII/SIRI on pain intensity/effusion-synovitis. The analyses were adjusted for confounders (age, sex, BMI, radiographic severity of the opposite knee, and anxio-depressive symptoms).</div></div><div><h3>Results</h3><div>Data from 225 participants (mean age: 61.1 (10.9), 68% female, mean BMI: 31.7 (7.7)) were analyzed. The associations for adjusted fat and pain intensity models were as follows: total body fat: β): - 0.03 (-0.54 to 0.46) and visceral fat: β (: -0.25 (-1.03 to 0.51)., The odds ratios for adjusted fat and effusion-synovitis models were total body fat: OR): 0.98 (0.92 to 1.05) and visceral fat: OR (): 1.01 (0.91 to 1.11)). Neither the main nor the interaction effects were significant.</div></div><div><h3>Conclusion</h3><div>Our preliminary results do not support an association of adiposity and its interaction with generalized inflammation with pain/effusion-synovitis adjusted for BMI. Further studies are needed.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"77 ","pages":"Article 152913"},"PeriodicalIF":4.4,"publicationDate":"2026-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145928552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to Chen and Liu regarding correspondence to “Development of a prediction model for progression of rheumatoid arthritis–associated interstitial lung disease using serologic and clinical factors: The prospective KORAIL cohort” 对Chen和Liu关于“基于血清学和临床因素的类风湿关节炎相关间质性肺病进展预测模型的建立：前瞻性KORAIL队列”的回应。

IF 4.4 2区医学 Q1 RHEUMATOLOGY

Seminars in arthritis and rheumatism

Pub Date : 2026-01-03 DOI: 10.1016/j.semarthrit.2026.152912

Sung Hae Chang , Misti L. Paudel , Eun Young Lee , Jeffrey A. Sparks

引用次数: 0

COVID-19 vaccination and systemic autoimmune rheumatic diseases: No evidence of disproportionately increased reporting in VAERS COVID-19疫苗接种和系统性自身免疫性风湿病：无证据表明VAERS报告比例增加。

IF 4.4 2区医学 Q1 RHEUMATOLOGY

Seminars in arthritis and rheumatism

Pub Date : 2026-01-02 DOI: 10.1016/j.semarthrit.2025.152911

Jacopo Ciaffi , Ginevra Torrigiani , Piero Ruscitti , Antonella Zambon , Francesco Ursini

Objectives

To investigate whether systemic autoimmune rheumatic diseases (SARDs) were disproportionately reported as adverse events following COVID-19 vaccination compared with other vaccines, using data from the Vaccine Adverse Event Reporting System (VAERS).

Methods

We conducted a retrospective disproportionality analysis of VAERS reports collected between December 2020 and December 2024. Reports were identified using a structured query based on MedDRA terms for specific SARDs, including polymyalgia rheumatica, giant cell arteritis, systemic lupus erythematosus, systemic sclerosis, Sjögren’s syndrome, myositis, and other vasculitides. For each disease, the proportional reporting ratio (PRR), reporting odds ratio (ROR), and Bayesian information component (IC) were calculated, comparing COVID-19 vaccines (BNT162b2, mRNA-1273, Ad26.COV2.S) with all other vaccines in VAERS. Analyses were further stratified by sex to explore consistency.

Results

Among approximately 680,000 valid adverse event reports, encompassing both COVID-19 and non–COVID-19 vaccines, no significant disproportionality signal was identified for any SARD. Polymyalgia rheumatica, giant cell arteritis, systemic lupus erythematosus, systemic sclerosis, Sjögren’s syndrome, and myositis showed no evidence of disproportionate reporting following COVID-19 vaccination. The category “other vasculitides” displayed a lower reporting frequency following COVID-19 vaccination compared with other vaccines. Stratified analyses yielded consistent findings across sex subgroups.

Conclusion

In a large national pharmacovigilance dataset, COVID-19 vaccines were not associated with a disproportionate increase in reports of any SARD. These results support the favorable safety profile of COVID-19 vaccines with respect to autoimmune rheumatic events, while highlighting the value of ongoing post-marketing surveillance for rare immune-mediated reactions.

目的：利用疫苗不良事件报告系统（VAERS）的数据，调查与其他疫苗相比，系统性自身免疫性风湿病（SARDs）作为COVID-19疫苗接种后不良事件的报告是否不成比例。方法：对2020年12月至2024年12月收集的VAERS报告进行回顾性歧化分析。使用基于MedDRA术语的结构化查询来识别特定SARDs的报告，包括风湿性多肌痛、巨细胞动脉炎、系统性红斑狼疮、系统性硬化症、Sjögren综合征、肌炎和其他血管疾病。对每种疾病计算比例报告比（PRR）、报告优势比（ROR）和贝叶斯信息分量（IC），比较COVID-19疫苗（BNT162b2、mRNA-1273、Ad26.COV2）。S)与所有其他VAERS疫苗。进一步按性别分层分析以探讨一致性。结果：在约68万份有效不良事件报告中，包括COVID-19和非COVID-19疫苗，未发现任何SARD的显著歧化信号。风湿病多肌痛、巨细胞动脉炎、系统性红斑狼疮、系统性硬化症、Sjögren综合征和肌炎在COVID-19疫苗接种后没有不成比例的报告证据。与其他疫苗相比，COVID-19疫苗接种后“其他血管”类别的报告频率较低。分层分析得出了跨性别亚组的一致结果。结论：在一个大型的国家药物警戒数据集中，COVID-19疫苗与任何SARD报告的不成比例的增加无关。这些结果支持了COVID-19疫苗在自身免疫性风湿病事件方面的良好安全性，同时强调了对罕见免疫介导反应进行持续上市后监测的价值。

{"title":"COVID-19 vaccination and systemic autoimmune rheumatic diseases: No evidence of disproportionately increased reporting in VAERS","authors":"Jacopo Ciaffi , Ginevra Torrigiani , Piero Ruscitti , Antonella Zambon , Francesco Ursini","doi":"10.1016/j.semarthrit.2025.152911","DOIUrl":"10.1016/j.semarthrit.2025.152911","url":null,"abstract":"<div><h3>Objectives</h3><div>To investigate whether systemic autoimmune rheumatic diseases (SARDs) were disproportionately reported as adverse events following COVID-19 vaccination compared with other vaccines, using data from the Vaccine Adverse Event Reporting System (VAERS).</div></div><div><h3>Methods</h3><div>We conducted a retrospective disproportionality analysis of VAERS reports collected between December 2020 and December 2024. Reports were identified using a structured query based on MedDRA terms for specific SARDs, including polymyalgia rheumatica, giant cell arteritis, systemic lupus erythematosus, systemic sclerosis, Sjögren’s syndrome, myositis, and other vasculitides. For each disease, the proportional reporting ratio (PRR), reporting odds ratio (ROR), and Bayesian information component (IC) were calculated, comparing COVID-19 vaccines (BNT162b2, mRNA-1273, Ad26.COV2.S) with all other vaccines in VAERS. Analyses were further stratified by sex to explore consistency.</div></div><div><h3>Results</h3><div>Among approximately 680,000 valid adverse event reports, encompassing both COVID-19 and non–COVID-19 vaccines, no significant disproportionality signal was identified for any SARD. Polymyalgia rheumatica, giant cell arteritis, systemic lupus erythematosus, systemic sclerosis, Sjögren’s syndrome, and myositis showed no evidence of disproportionate reporting following COVID-19 vaccination. The category “other vasculitides” displayed a lower reporting frequency following COVID-19 vaccination compared with other vaccines. Stratified analyses yielded consistent findings across sex subgroups.</div></div><div><h3>Conclusion</h3><div>In a large national pharmacovigilance dataset, COVID-19 vaccines were not associated with a disproportionate increase in reports of any SARD. These results support the favorable safety profile of COVID-19 vaccines with respect to autoimmune rheumatic events, while highlighting the value of ongoing post-marketing surveillance for rare immune-mediated reactions.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"77 ","pages":"Article 152911"},"PeriodicalIF":4.4,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145917507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biologic switching challenges in psoriatic arthritis: A pediatric reflection, letter to "biologic switching in psoriatic arthritis: Insights from real-world data and key risk factors" 银屑病关节炎的生物转换挑战：儿科反思，致“银屑病关节炎的生物转换：来自现实世界数据和关键危险因素的见解”的信

IF 4.4 2区医学 Q1 RHEUMATOLOGY

Seminars in arthritis and rheumatism

Pub Date : 2026-01-01 DOI: 10.1016/j.semarthrit.2025.152910

Sıla Atamyıldız Uçar, Eray Tunce, Betül Sözeri

引用次数: 0

Response to letter to the editor regarding "Nailfold Capillaroscopy as a predictor of cardiovascular events and mortality in systemic sclerosis" 关于“甲襞毛细血管镜检查作为系统性硬化症心血管事件和死亡率的预测指标”致编辑的信的回复

IF 4.4 2区医学 Q1 RHEUMATOLOGY

Seminars in arthritis and rheumatism

Pub Date : 2026-01-01 DOI: 10.1016/j.semarthrit.2025.152909

Carlos Valera-Ribera, Juan José Alegre-Sancho, Joaquín Lacasa-Molina, Montserrat Robustillo-Villarino, Javier Narváez

引用次数: 0

Comment on "Risk and temporal trends of heart failure subtypes in rheumatoid arthritis" 对“类风湿关节炎心衰亚型的风险和时间趋势”的评论

IF 4.4 2区医学 Q1 RHEUMATOLOGY

Seminars in arthritis and rheumatism

Pub Date : 2026-01-01 DOI: 10.1016/j.semarthrit.2025.152906

Lin Zhang , Lidan Yang

引用次数: 0

The efficacy of metformin for pain, function, and quality of life in knee osteoarthritis: A systematic review and meta-analysis 二甲双胍对膝关节骨关节炎患者疼痛、功能和生活质量的疗效：一项系统回顾和荟萃分析

IF 4.4 2区医学 Q1 RHEUMATOLOGY

Seminars in arthritis and rheumatism

Pub Date : 2025-12-31 DOI: 10.1016/j.semarthrit.2025.152908

Chi-Lan Kao , Shih-Ming Chen , Chih-Cheng Hsieh , Tzu-Rong Peng , Pei-Yun Tsai , Chia-Yu Lin , Ming-Chia Lee

Background

Knee osteoarthritis (KOA) is a leading cause of disability worldwide; however current therapies offer only symptomatic relief. Metformin, a widely used antidiabetic agent, has been demonstrated to have anti-inflammatory and chondroprotective effects in preclinical models, suggesting its KOA modifying properties.

Methods

We conducted a systematic review and meta-analysis of randomized controlled trials evaluating the effects of metformin in patients with KOA. A comprehensive search of PubMed, Embase, and Cochrane Library was performed up to May 2025. Two reviewers independently screened studies and extracted data. Statistical analyses were conducted using a random-effects model to account for between-study heterogeneity. Subgroup analyses based on formulation, treatment duration, and nonsteroidal anti-inflammatory drugs (NSAIDs) co-administration were also performed.

Results

Five studies (n = 337) were included. Metformin significantly reduced pain scores (standardized mean difference [SMD] = −1.295; 95 % confidence interval [CI]: −2.063 to −0.526) and stiffness (SMD = −0.746; 95 % CI: −1.385 to −0.107), improved physical function (SMD = −2.042; 95 % CI: −3.372 to −0.712), and health-related quality of life (SMD = −1.505; 95 % CI: −2.896 to −0.115). Effects were consistent regardless of oral or topical metformin use, treatment duration, and NSAID use, although the benefits were greater when metformin was combined with NSAIDs.

Conclusion

While metformin demonstrated consistent benefits in pain and functional outcomes, these findings should be interpreted as symptomatic and adjunctive effects rather than definitive disease modification. Future trials incorporating structural endpoints are needed to confirm disease-modifying potential.

膝骨关节炎（KOA）是世界范围内致残的主要原因；然而，目前的治疗只能缓解症状。二甲双胍是一种广泛使用的降糖药，在临床前模型中已被证明具有抗炎和软骨保护作用，表明其具有改变KOA的特性。方法对评价二甲双胍对KOA患者疗效的随机对照试验进行系统回顾和荟萃分析。对PubMed， Embase和Cochrane Library进行了全面的检索，直至2025年5月。两位审稿人独立筛选研究并提取数据。采用随机效应模型进行统计分析，以解释研究间的异质性。基于处方、治疗时间和非甾体抗炎药（NSAIDs）联合使用的亚组分析也进行了。结果纳入5项研究（n = 337）。二甲双胍显著降低了疼痛评分（标准化平均差[SMD] = - 1.295； 95%可信区间[CI]: - 2.063至- 0.526）和僵硬（SMD = - 0.746; 95% CI: - 1.385至- 0.107），改善了身体功能（SMD = - 2.042; 95% CI: - 3.372至- 0.712），以及与健康相关的生活质量（SMD = - 1.505; 95% CI: - 2.896至- 0.115）。无论口服或外用二甲双胍、治疗持续时间和使用非甾体抗炎药，效果都是一致的，尽管二甲双胍与非甾体抗炎药联合使用的效果更大。结论：虽然二甲双胍在疼痛和功能结局方面表现出一致的益处，但这些发现应被解释为症状和辅助作用，而不是确定的疾病改变。未来的试验需要结合结构终点来确认疾病改善的潜力。

{"title":"The efficacy of metformin for pain, function, and quality of life in knee osteoarthritis: A systematic review and meta-analysis","authors":"Chi-Lan Kao , Shih-Ming Chen , Chih-Cheng Hsieh , Tzu-Rong Peng , Pei-Yun Tsai , Chia-Yu Lin , Ming-Chia Lee","doi":"10.1016/j.semarthrit.2025.152908","DOIUrl":"10.1016/j.semarthrit.2025.152908","url":null,"abstract":"<div><h3>Background</h3><div>Knee osteoarthritis (KOA) is a leading cause of disability worldwide; however current therapies offer only symptomatic relief. Metformin, a widely used antidiabetic agent, has been demonstrated to have anti-inflammatory and chondroprotective effects in preclinical models, suggesting its KOA modifying properties.</div></div><div><h3>Methods</h3><div>We conducted a systematic review and meta-analysis of randomized controlled trials evaluating the effects of metformin in patients with KOA. A comprehensive search of PubMed, Embase, and Cochrane Library was performed up to May 2025. Two reviewers independently screened studies and extracted data. Statistical analyses were conducted using a random-effects model to account for between-study heterogeneity. Subgroup analyses based on formulation, treatment duration, and nonsteroidal anti-inflammatory drugs (NSAIDs) co-administration were also performed.</div></div><div><h3>Results</h3><div>Five studies (<em>n</em> = 337) were included. Metformin significantly reduced pain scores (standardized mean difference [SMD] = −1.295; 95 % confidence interval [CI]: −2.063 to −0.526) and stiffness (SMD = −0.746; 95 % CI: −1.385 to −0.107), improved physical function (SMD = −2.042; 95 % CI: −3.372 to −0.712), and health-related quality of life (SMD = −1.505; 95 % CI: −2.896 to −0.115). Effects were consistent regardless of oral or topical metformin use, treatment duration, and NSAID use, although the benefits were greater when metformin was combined with NSAIDs.</div></div><div><h3>Conclusion</h3><div>While metformin demonstrated consistent benefits in pain and functional outcomes, these findings should be interpreted as symptomatic and adjunctive effects rather than definitive disease modification. Future trials incorporating structural endpoints are needed to confirm disease-modifying potential.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"77 ","pages":"Article 152908"},"PeriodicalIF":4.4,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145928550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum to “Magnetic resonance imaging for adult idiopathic inflammatory myopathies: a scoping review of protocols, grading systems and applications”[Seminars in Arthritis and Rheumatism Volume 75, (2025) 152865] 对“成人特发性炎性肌病的磁共振成像：协议，分级系统和应用的范围审查”的勘误[关节炎和风湿病研讨会，第75卷，（2025）152865]

IF 4.4 2区医学 Q1 RHEUMATOLOGY

Seminars in arthritis and rheumatism

Pub Date : 2025-12-31 DOI: 10.1016/j.semarthrit.2025.152899

Jessica A. Day , Daniel Brito de Araújo , Mickael Essouma , Edoardo Conticini , Lisa G. Rider , Daren Gibson , Adriana Maluf Elias , Claudia Saad Magalhães , Simone Appenzeller , Adam Schiffenbauer , Anneke J van der Koi , Siamak Moghadam-Kia , Vitor Tavares Paula , Julio Brandão Guimarães , Edoardo Marrani , Andrea Schwarz Doria , Samuel Katsuyuki Shinjo

引用次数: 0

Risk and temporal trends of heart failure subtype risk in Rheumatoid Arthritis 类风湿关节炎心衰亚型风险的风险和时间趋势

IF 4.4 2区医学 Q1 RHEUMATOLOGY

Seminars in arthritis and rheumatism

Pub Date : 2025-12-30 DOI: 10.1016/j.semarthrit.2025.152905

Tate M. Johnson , Bryant R. England

引用次数: 0

Determining the best discriminatory physical functioning outcome measurement instrument for psoriatic arthritis trials: A meta-epidemiological study 确定银屑病关节炎试验中最佳歧视性身体功能结果测量工具：一项荟萃流行病学研究。

IF 4.4 2区医学 Q1 RHEUMATOLOGY

Seminars in arthritis and rheumatism

Pub Date : 2025-12-29 DOI: 10.1016/j.semarthrit.2025.152907

Ying-Ying Leung , Tobias Haugegaard , Tommy Kok Annfeldt , Richard Holland , Vibeke Strand , Philip Mease , Peter Tugwell , George A. Wells , Beverley J. Shea , Ashish J. Mathew , Niti Goel , Christine Lindsay , Alexis Ogdie , Ana-Maria Orbai , Laura C. Coates , Dafna D. Gladman , William Tillett , Jeffrey Chau , Robin Christensen

Objectives

To empirically compare the discriminant capacities of three outcome measurement instruments for assessment of physical functioning for psoriatic arthritis (PsA): HAQ-DI, SF36-PF and SF36-PCS.

Methods

We applied a network meta-analysis technique in a sample of randomized trials (RCTs) for PsA. For randomized comparison, we calculated net effect size estimates for each outcome measurement instrument using standardized mean differences (SMDs); positive values indicated a beneficial effect of the intervention compared to the control groups. We analyzed the differences between outcome measurement instruments at the trial level by applying a multiple-treatment meta-analysis to compare the SMDs within and across randomized comparisons for each outcome measurement instrument.

Results

From 42 articles (31 RCTs), 57, 18, and 18 randomized comparisons enabled a direct comparison between HAQ-DI and SF36-PCS (difference in SMDs: 0.057, 95 % confidence interval, CI: 0.003 to 0.110), SF36-PF and SF36-PCS (difference in SMDs: 0.101, 95 % CI: 0.018 to 0.184); and HAQ-DI and SF36-PF (difference in SMDs:0.059, 95 % CI:0.142 to 0.024), respectively. The network meta-analysis technique confirmed that both HAQ-DI and SF36-PF were more responsive to change than SF36-PCS, with differences between SMDs of 0.057 (95 % CI: 0.003 to 0.110) and 0.109 (95 % CI: 0.032 to 0.185), respectively. No difference in discriminatory capacity between HAQ-DI and SF36-PF was noted.

Conclusions

HAQ-DI and SF-36-PF were equally responsive to change and superior to SF36-PCS in PsA RCTs. We illustrated a new method for quantitative comparison of the performance of different outcome measurement instruments for a particular domain.

目的：实证比较HAQ-DI、SF36-PF和SF36-PCS三种结果测量工具评估银屑病关节炎（PsA）身体功能的判别能力。方法：我们在PsA随机试验（rct）样本中应用网络荟萃分析技术。对于随机比较，我们使用标准化平均差异（SMDs）计算每个结果测量工具的净效应大小估计值；与对照组相比，正值表明干预的有益效果。我们在试验水平上分析了结果测量工具之间的差异，采用多治疗荟萃分析来比较每种结果测量工具的随机比较内部和之间的smd。结果：在42篇文章（31项随机对照试验）中，57、18和18项随机比较可以直接比较HAQ-DI和SF36-PCS （SMDs差异0.057,95%可信区间CI: 0.003至0.110）、SF36-PF和SF36-PCS (SMDs差异0.101,95%可信区间CI: 0.018至0.184)；HAQ-DI和SF36-PF （smd差异为0.059,95% CI为0.142 ~ 0.024）。网络荟萃分析技术证实，HAQ-DI和SF36-PF对变化的反应比SF36-PCS更敏感，smd之间的差异分别为0.057 （95% CI: 0.003至0.110）和0.109 （95% CI: 0.032至0.185）。HAQ-DI和SF36-PF之间的区分能力没有差异。结论：在PsA随机对照试验中，HAQ-DI和SF-36-PF对变化的反应相同，且优于SF36-PCS。我们说明了一种新的方法来定量比较不同的结果测量仪器的性能为特定领域。

{"title":"Determining the best discriminatory physical functioning outcome measurement instrument for psoriatic arthritis trials: A meta-epidemiological study","authors":"Ying-Ying Leung , Tobias Haugegaard , Tommy Kok Annfeldt , Richard Holland , Vibeke Strand , Philip Mease , Peter Tugwell , George A. Wells , Beverley J. Shea , Ashish J. Mathew , Niti Goel , Christine Lindsay , Alexis Ogdie , Ana-Maria Orbai , Laura C. Coates , Dafna D. Gladman , William Tillett , Jeffrey Chau , Robin Christensen","doi":"10.1016/j.semarthrit.2025.152907","DOIUrl":"10.1016/j.semarthrit.2025.152907","url":null,"abstract":"<div><h3>Objectives</h3><div>To empirically compare the discriminant capacities of three outcome measurement instruments for assessment of physical functioning for psoriatic arthritis (PsA): HAQ-DI, SF36-PF and SF36-PCS.</div></div><div><h3>Methods</h3><div>We applied a network meta-analysis technique in a sample of randomized trials (RCTs) for PsA. For randomized comparison, we calculated net effect size estimates for each outcome measurement instrument using standardized mean differences (SMDs); positive values indicated a beneficial effect of the intervention compared to the control groups. We analyzed the differences between outcome measurement instruments at the trial level by applying a multiple-treatment meta-analysis to compare the SMDs within and across randomized comparisons for each outcome measurement instrument.</div></div><div><h3>Results</h3><div>From 42 articles (31 RCTs), 57, 18, and 18 randomized comparisons enabled a direct comparison between HAQ-DI and SF36-PCS (difference in SMDs: 0.057, 95 % confidence interval, CI: 0.003 to 0.110), SF36-PF and SF36-PCS (difference in SMDs: 0.101, 95 % CI: 0.018 to 0.184); and HAQ-DI and SF36-PF (difference in SMDs:0.059, 95 % CI:0.142 to 0.024), respectively. The network meta-analysis technique confirmed that both HAQ-DI and SF36-PF were more responsive to change than SF36-PCS, with differences between SMDs of 0.057 (95 % CI: 0.003 to 0.110) and 0.109 (95 % CI: 0.032 to 0.185), respectively. No difference in discriminatory capacity between HAQ-DI and SF36-PF was noted.</div></div><div><h3>Conclusions</h3><div>HAQ-DI and SF-36-PF were equally responsive to change and superior to SF36-PCS in PsA RCTs. We illustrated a new method for quantitative comparison of the performance of different outcome measurement instruments for a particular domain.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"77 ","pages":"Article 152907"},"PeriodicalIF":4.4,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145912736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Seminars in arthritis and rheumatism

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀